Peter Vestergaard Rasmussen

Associate professor

Aarhus University

Denmark

Research Interests

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (14)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (13)

Tobias Sejbaek

University of Southern Denmark

DENMARK

View details

Finn Sellebjerg

Professor

Copenhagen University Hospital

DENMARK

View details

Jørgen Bo Hasselstrøm

Aarhus University

DENMARK

View details

Helle Hvilsted Nielsen

University of Southern Denmark

DENMARK

View details

Eva Sædder

Aarhus University

DENMARK

View details

Zsolt Illes

Professor

DENMARK

View details

Rikke M Hansen

Aarhus University

DENMARK

View details

Anders Svenningsson

Karolinska Institutet

SWEDEN

View details

Helge Kasch

Aarhus University

DENMARK

View details

Justin Yehuda Garber

Clinical Senior Lecturer

University of Sydney

AUSTRALIA

View details

Melinda Magyari

Associate professor

University of Copenhagen

DENMARK

View details

Jiří Drahota

General University Hospital in Prague

CZECH REPUBLIC

View details

Izanne Roos

University of Melbourne

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Peter Vestergaard Rasmussen

Research Interests

Contact this professor

Articles (14)

Prognostic factors for disease activity in newly diagnosed teriflunomide-treated patients with multiple sclerosis: a nationwide Danish study

Pharmacokinetics and pharmacodynamics of cannabis-based medicine in a patient population included in a randomized, placebo-controlled, clinical trial

Shedding Light on the Black Box of Rehabilitation: Differential Short- and Long-Term Effects of Multidisciplinary Multiple Sclerosis Rehabilitation

Cannabis-Based Medicine for Neuropathic Pain and Spasticity—A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial

Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.

Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 13 years of follow-up

Predictors of treatment switching in the Big Multiple Sclerosis Data Network

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study

Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies

The Effect of Cannabis-Based Medicine on Neuropathic Pain and Spasticity in Patients with Multiple Sclerosis and Spinal Cord Injury: Study Protocol of a National Multicenter Double-Blinded, Placebo-Controlled Trial

Ocrelizumab treatment in Multiple Sclerosis: A Danish population‐based cohort study

Application of definitions for conversion to secondary progressive MS in a Danish nationwide population

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

Collaborators (13)

Tobias Sejbaek

Finn Sellebjerg

Jørgen Bo Hasselstrøm

Helle Hvilsted Nielsen

Eva Sædder

Zsolt Illes

Rikke M Hansen

Anders Svenningsson

Helge Kasch

Justin Yehuda Garber

Melinda Magyari

Jiří Drahota

Izanne Roos

Make your next move.